NextCell Pharma AB
NXTCL | ST
Overview
Corporate Details
- ISIN(s):
- SE0009723125 (+1 more)
- LEI:
- 549300PBFGB5JYKXGA45
- Country:
- Sweden
- Address:
- Hälsovägen 7, 141 57 Huddinge
- Website:
- https://nextcellpharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
NextCell Pharma AB is a clinical-stage biotechnology company specializing in the development and commercialization of advanced cell therapies using mesenchymal stromal cells (MSCs). Its lead drug candidate, ProTrans, is an allogeneic, off-the-shelf cell therapy product developed with a patented selection algorithm. ProTrans is primarily being investigated in Phase 2 clinical trials for the treatment of autoimmune diseases, particularly type 1 diabetes. Through strategic collaborations, such as with FUJIFILM Biosciences, NextCell also provides standardized MSC products, cell cultivation, and cryopreservation solutions to researchers and developers. The company also operates Cellaviva, a service for the private banking of stem cells.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for NextCell Pharma AB.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all NextCell Pharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NextCell Pharma AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
